Funder
National Key Research and Development Program
Natural Science Foundation of Hebei Province
Hebei Provincial Administration of Traditional Chinese Medicine
Publisher
Springer Science and Business Media LLC
Subject
Genetics (clinical),Cardiology and Cardiovascular Medicine,Pharmaceutical Science,Genetics,Molecular Medicine
Reference51 articles.
1. Upadhya, B., & Kitzman, D. W. (2020). Heart failure with preserved ejection fraction: New approaches to diagnosis and management. Clinical Cardiology, 43(2), 145–155. https://doi.org/10.1002/clc.23321
2. Shear, F. E. (2019). Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: Clinical perspectives. American Journal of Cardiovascular Diseases, 9(5), 91–108.
3. Shah, K. S., Xu, H., Matsouaka, R. A., Bhatt, D. L., Heidenreich, P. A., Hernandez, A. F., Devore, A. D., Yancy, C. W., & Fonarow, G. C. (2017). Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. Journal of the American College of Cardiology, 70(20), 2476–2486. https://doi.org/10.1016/j.jacc.2017.08.074
4. Minamisawa, M., Claggett, B., Suzuki, K., Hegde, S. M., Shah, A. M., Desai, A. S., Lewis, E. F., Shah, S. J., Sweitzer, N. K., Fang, J. C., Anand, I. S., O’Meara, E., Rouleau, J. L., Pitt, B., Pfeffer, M. A., Solomon, S. D., & Vardeny, O. (2021). Association of hyper-polypharmacy with clinical outcomes in heart failure with preserved ejection fraction. Circulation. Heart Failure, 14(11), e8293. https://doi.org/10.1161/CIRCHEARTFAILURE.120.008293
5. Simmonds, S. J., Cuijpers, I., Heymans, S., Jones, E. (2020). Cellular and molecular differences between HFpEF and HFrEF: A step ahead in an improved pathological understanding. Cells-Basel 9(1). https://doi.org/10.3390/cells9010242
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献